Home › Funds › Davern Capital Partners, LP › MLYS
Davern Capital Partners, LP position in MLYS
MINERALYS THERAPEUTICS INC · Health Care
Davern Capital Partners, LP reported holding 695,152 shares of MLYS (MINERALYS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$17.5M, representing 3.40% of its reported portfolio and ranking #11 among its reported holdings. Davern Capital Partners, LP has disclosed MLYS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Davern Capital Partners, LP's MLYS position evolved
Davern Capital Partners, LP first disclosed a stake in MLYS in Q4 2025 at 210,648 shares (US$7.6M). The position peaked in Q2 2026 at 858,753 shares, worth US$23.2M. Across 4 filings, Davern Capital Partners, LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 695,152 shares valued at US$17.5M — a reduction of -163,601 shares quarter over quarter.. Notable position changes include a 112% increase in Q1 2026 (shares were roughly flat over the following quarter), a 92% increase in Q2 2026 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 210.65K | $7.64M | New |
| Q1 2026 | 447.15K | $12.11M | Add |
| Q2 2026 | 858.75K | $23.17M | Add |
| Q3 2026 | 695.15K | $17.47M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLYS and 13F data
MLYS (MINERALYS THERAPEUTICS INC) is a Health Care company. 53 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLYS
- RA CAPITAL MANAGEMENT, L.P. 7.69M sh · $207.55M · Q2 2026
- Catalys Pacific, LLC 7.80M sh · $196.00M · Q3 2026
- Samsara BioCapital, LLC 5.87M sh · $158.40M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M sh · $106.79M · Q2 2026
- Laurion Capital Management LP 2.51M sh · $67.62M · Q2 2026
- ORBIMED ADVISORS LLC 2.11M sh · $56.94M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 1.56M sh · $42.20M · Q2 2026
- Andera Partners 1.59M sh · $40.00M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.47M sh · $39.66M · Q2 2026
- Ghisallo Capital Management LLC 1.12M sh · $30.35M · Q2 2026
- Logos Global Management LP 1.05M sh · $28.33M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.04M sh · $28.06M · Q2 2026
More on Davern Capital Partners, LP
FAQ
How long has Davern Capital Partners, LP held MLYS?
Davern Capital Partners, LP has disclosed MLYS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Davern Capital Partners, LP's current position in MLYS?
As of Q3 2026, Davern Capital Partners, LP holds 695.15K shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $17.47M, representing 3.40% of its reported portfolio and ranking #11.
Has Davern Capital Partners, LP been buying or selling MLYS?
In the latest 13F filing (Q3 2026), Davern Capital Partners, LP reduced its position in MLYS. The position peaked in Q2 2026 at 858.75K shares.
Which other funds hold MLYS?
Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.